Maraviroc, risks and benefits: A review of the clinical literature

Expert Opinion on Drug Safety

Volumn 7, Issue 5, 2008, Pages 559-569

  Emmelkamp, Jetske M ^a   Rockstroh, Jürgen K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Antiretroviral therapy; CCR5 co receptor antagonist; CCR5 inhibitors; Drug drug interactions; HIV 1; Maraviroc; Tropism

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTIRETROVIRUS AGENT; APLAVIROC; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; COTRIMOXAZOLE; DARUNAVIR PLUS RITONAVIR; DEXTRO ALANINE1 PEPTIDE T AMIDE; EFAVIRENZ; ENFUVIRTIDE; ISONIAZID; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ASTHENIA; BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GINGIVITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOMA; MEDICAL LITERATURE; MULTIPLE DRUG DOSE; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PHASE 3 CLINICAL TRIAL;

CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOHEXANES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; TRIAZOLES;

EID: 54449094222     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.5.559     Document Type: Review

References (53)

1. Biswas P, Nozza S, Scarlatti G, et al. Oral CCR5 inhibitors: will they make it through? Expert Opin Investig Drugs 206;15(5):451-64
2. Biswas P, Tambusi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother 2007;8(7):923-33
3. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-32
4. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382(6593):722-5
5. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals fort be treatment of HIV infection. Antivir Chem Chemother 2005;6(16):339-54
6. Lederman M, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role on HIV infection and treatment. JAMA 2006(296):815-26
7. Hunt P, Harringa P. Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926
8. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. XVI International AIDS Conference (IAC); 2006; Toronto
9. Fätkenheuer G, Pozniak A, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;(11):1170-2
10. Lalezari J, Goodrich J, deJesus E, et al. Efficacy and safety of Maraviroc in antiretroviral treatment experienced patients infected with CCRS-tropic HIV-1: 48 week results of MOTIVATE 1. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007; Chicago
11. Fätkenheuer G. Efficacy and safety of Maraviroc plus optimized background therapy in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-week results. 11th European AIDS Conference (EACS); 2007
12. Abel S, van der Ryst E, Muirhead GJ, er al. Pharmacokinetics of single and multiple oral doses of UK-427,857-a novel ccr5 antagonist in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections (CROI); 2003; Boston, USA
13. McHale M, et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
14. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/ 3 study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections (CROI); 2007; Los Angeles
15. Nelson M, Fätkenheuer G, Kounourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients/infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14th Conference on Retroviruses and Opportunistic Infections (CROI); 2007; Los Angeles
16. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [poster 792]. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston
17. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine/lamivudine), for the treatment of antiretroviral-naive subjects infected with R5 HIV 1: week 48 results of the MERIT study. 4th IAS; 2007; Sydney
18. Mosley M, Smith-Burchnell C, Mori J, et al. Resistance to the CCR5 antagonist Maraviroc is characterised by dose-response curves that display a reduction in maximal inhibition. 13th Conference on Retroviruses and Opportunistic Infections (CROI); 2006; Denver
19. Pugach P, Marozsan A, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 207;361(1):212-28
20. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80(10):4909-20
21. Steel HM. Special presentation on aplaviroc-related hepatotoxicity. 10th European AIDS Conference (EACS); 2005; Dublin
22. Mayer H. Case study of a patient with serious hepatotoxicity in maraviroc IIB/III trial, Targeting HIV Entry - First International Workshop; 2005; Bethesda
23. Clotet B. CCR5 inhibitors: promising yet challenging. J Infect Dis 2007;196:178
24. Reyes G. Development of CCR5 antagonists as a new class of anti-HIV therapeutic. 8th Conference on Retroviruses and Opportunistic Infections (CROI); 2001; Chicago
25. Davis JD, Hackman F, Layton G, et al. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 2008;65(Suppl 1):68-75
26. Schering-Plough Corp. Schering-Plough provides an update on Phase II study of vicriviroc: study continues in HIV-treatment experienced patients. Press release 3 March 2006. Available from: www.schering-plough.com
27. Gulick R, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007; 196 (2):304-12
28. Dean M, Jacobson L, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5- 32 mutation. Cancer Res 1999;59:3561-4
29. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results. 4th IAS Conference; 2007
30. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203(1):35-40
31. Ahlenstiel G, Woitas R, Rockstroh JK, Spengler U. CC chemokin receptor 5 (CCR5) in hepatitis C-at the crossroads of the antiviral immune response? J Antimicrob Chemother 2004;53:895-8
32. Ayoub A, van der Ryst E, Turner K, McHale M. A review of the markers of immune function during the Maraviroc phase 1 and 2a studies. 14th Conference on Retrovirsuses and Opportunistic Infections (CROI); 2007; Los Angeles
33. Peters C, Kawabata T, Syntin P, et al. Assessment of immunotoxic potential of Maraviroc in cynomolgus monkeys. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005; Washington
34. Karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003;17:2561-9
35. Karlsson U, Antonsson L, Owman C, et al. Coreceptor use in paired plasma and cerebrospinal fluid HIV-1 isolates. 46th ICAAC; 2006; San Francisco
36. Goodkin K, Vitiello B, Lyman WD, et al. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol 2006;(12):178-89
37. Abel S, Taylor-Worth R, Ridgway C, et al. Effect of boosted tipranavir on the pharmacokinetics of Maraviroc (UK 427,857) in healthy volunteers. 10th European AIDS Conference (EACS); 2005; Dublin
38. Abel S, Russell D, Ridgway C, Muirhead G. Overview of the drug-drug interaction data for maraviroc. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005; Quebec, Canada
39. Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427,857 in HIV + ve subjects. 12th Conference on Retroviruses and Opportunistic Infections (CROI); 2005; Boston
40. Abel S, Russell D, Ridgway C et al. Effect of CCR5 antagonist UK 427,857 on the pharmacokinetics of CYP3A4 substrates in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome, Italy
41. Abel S, Whitlock L, Ridgway C, et al. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427, 857 in young women. Proceedings of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 14 - 17 September 2003; Chicago.
42. Pfizer. Data on file. FDA Antiviral Drugs Advisory Committee (AVDAC) meeting held 24 Apri1 2007. Available from: http://www.fda.gov/ohrms/ dockets/ac/cder07.htm#AntiviralDrugs
43. Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1 - 3 Apri1 2004; Rome, Italy.
44. US Department of Health and Human Services, Federal Food and Drug Administration (FDA). Medication guide: highlights of precribing information, Selzentry (maraviroc) tablets. Initial US approval 2007. Available from: www.fda.gov
45. US Department of Health and Human Services, Federal Food and Drug Administration (FDA). FDA approves new HIV-drug: raltegravir tablets used in combination with other antiretroviral agents. FDA news for immediate release; 16 October 2007. Available from: www.fda.gov
46. Grinsztejn B, Nguyen B, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 2007;369(9569):1261-9
47. Cooper D, Gatell J, Rockstroh J, et al. 48-Week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston
48. Steigbigel R, Kumar R, Eron J, et al. 48-Week results from BENCHMRK-2, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston
49. Madruga JV,, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38
50. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48
51. US Department of Health and Human Services, Federal Food and Drug Administration (FDA). FDA approves new HIV drug after priority review. Etravirine tablets used in combination with other antiretroviral agents. FDA news for immediate release; 18 January 2008. Available from: www.fda.gov
52. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003;(17):2487-94
53. Sankatsing SUC, Weverling G, Peeters M, et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003;17(18):2623-7